RFI Alzheimer’s Research Program (AZRP) Public
Active, responses due . Full description on SAM.gov.
Overview
- Response deadline
- 4:00 PM EST
- Posted
- October 27, 2026
- Notice type
- Sources Sought
- NAICS
- 541714: Research and Development in Biotechnology (except Nanobiotechnology)
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY
- Place of performance
- Frederick, Maryland, 21702
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- HT9427RFI2027AZRP
- Notice ID
- dd5a1535217041769cb27f958c402a22
Description
The Congressionally Directed Medical Research Programs (CDMRP) seeks feedback to inform the fiscal year 2027 (FY27) Alzheimer’s Research Program (AZRP) research focus areas and associated research funding opportunities.
Although FY27 federal funds have not yet been appropriated, the AZRP is collecting this information solely to support strategic program planning. This inquiry does not commit the program to incorporating this feedback into FY27 or any future AZRP funding opportunities. The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public.
This RFI should not be construed as a solicitation or an obligation on the part of the AZRP or the Department of War (DoW).
BACKGROUND: The CDMRP represents a unique partnership between the U.S. Congress, the military, and the public to fund innovative and impactful medical research in targeted program areas. The CDMRP AZRP’s vision is to mitigate the impact of Alzheimer's and related dementias associated with TBI, military, and diverse risks. The AZRP’s mission is to fund impactful, solution-oriented research to address critical needs and improve quality of life for Service Members, Veterans, their Families, and the public who are living with Alzheimer's disease and related dementias.
Appropriations for the AZRP from FY11-26 totaled $228 million. As of October 2026, FY27 funds for the AZRP have not been appropriated. If appropriated, the CDMRP will utilize its two-tier review process https://cdmrp.health.mil/about/2tierRevProcess) to efficiently manage the AZRP. Additional information about the AZRP can be found here: https://cdmrp.health.mil/azrp/
RESPONSE INSTRUCTIONS: Please provide responses to this RFI by clicking on the following link:
https://www.surveymonkey.com/r/FY27-AZRP-RFI
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
Files (2)
Links (1)
- FY27 AZRP Request for Information Survey Monkeywww.surveymonkey.comPosted
Lifecycle
- 1Version 1Sources SoughtCurrent
RFI Alzheimer’s Research Program (AZRP) Public
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The Congressionally Directed Medical Research Programs (CDMRP) seeks feedback to inform potential future Lupus Research Program (LRP) focus areas and associated research funding opportunities. Although fiscal year 2027 (FY27) funds have not been appropriated, the LRP is requesting this information to support program planning processes. The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public. This RFI is for information and planning purposes only and should not be construed as a solicitation or an obligation on the part of the LRP or the Department of War. BACKGROUND: The CDMRP represents a unique partnership between the U.S. Congress, the military, and the public to fund innovative and impactful medical research in targeted program areas. The CDMRP LRP’s vision is to cure lupus through partnership of scientists, clinicians and persons affected by lupus. The LRP’s mission is to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life of patients, including Service Members and their Families, Veterans and the general public. Appropriations for the LRP from FY17-24 and FY26 totaled $75 million. As of October 2026, FY27 funds for the LRP have not been appropriated. If appropriated, the CDMRP will utilize its two-tier review process https://cdmrp.health.mil/about/2tierRevProcess) to efficiently manage the LRP. Additional information about the LRP can be found here: https://cdmrp.health.mil/lrp/ RESPONSE INSTRUCTIONS: Please provide responses to this RFI by clicking on the following link: https://www.surveymonkey.com/r/FY27-LRP-RFI | 100% | Market Research | 11/16/2026 |
The Congressionally Directed Medical Research Programs (CDMRP) seeks feedback to inform the fiscal year 2027 (FY27) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) research focus areas and associated research funding opportunities. Although FY27 federal funds have not yet been appropriated, TBIPRP is collecting this information solely to support strategic program planning. This inquiry does not commit the program to incorporating this feedback into FY27 or any future TBIPHRP funding opportunities. The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public. This RFI should not be construed as a solicitation or an obligation on the part of the TBIPHRP or the Department of War (DoW). BACKGROUND: The CDMRP represents a unique partnership between the U.S. Congress, the military, and the public to fund innovative and impactful medical research in targeted program areas. The CDMRP TBIPHRP’s vision is to optimize the prevention, assessment, and treatment of psychological health conditions and/or traumatic brain injuries. The TBIPHRP’s mission is to fund research to understand, prevent and treat psychological health conditions and/or traumatic brain injuries that accelerates solutions to improve the health and healthcare of Service Members, their Families, Veterans, and the American public. Appropriations for the TBIPHRP from FY21-24 and FY26 totaled $740.5 million. As of October 2026, FY27 funds for the TBIPHRP have not been appropriated. If appropriated, the CDMRP will utilize its two-tier review process https://cdmrp.health.mil/about/2tierRevProcess) to efficiently manage the TBIPHRP. Additional information about the TBIPHRP can be found here: https://cdmrp.health.mil/tbiphrp/ RESPONSE INSTRUCTIONS: Please provide responses to this RFI by clicking on the following link: https://www.surveymonkey.com/r/FY27-TBIPHRP-RFI | 96% | Market Research | 12/11/2026 |
The purpose of this Special Notice (SN) is to provide public notification of additional research areas of interest to the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO), specifically for the forthcoming Laguna program. When released, the solicitation will be made available at https://sam.gov/. Additionally, this SN may be amended with a draft solicitation when available. | 65% | Special Notice | 11/30/2026 |
This Request for Prototype Proposal (RPP) is being issued under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022 by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency, Portfolio Acquisition Executive Medical Products (PAE MP), Warfighter Protection and Acute Care Project Management Office (WPAC PMO) located in Frederick, Maryland, at Fort Detrick. The requirement is for Analgesic Product for Battlefield Use. Please see the attached RPP and attachments for additional information. Amendment 0001 The purpose of Amendment 0001 is to: 1. Amend the Request for Prototype Proposal (RPP) as follows: - Extend the proposal due date from 30 July 2026 to 14 August 2026 (RPP Amendment 0001, page 1 and page 17). No additional questions/phone calls regarding the RPP will be accepted. - Update the word “drug” to “product” to align with the language (RPP Amendment 0001, page 2, section 1.1, third paragraph) - Clarify language regarding the Spend Plan (RPP Amendment 0001, page 13, section 3.5 Volume III: Administrative and Cost Volume, Attachment E – Cost Sheet Template with priced milestones, first paragraph). - Add additional Vendor requirements (RPP Amendment 0001, page 15, section 3.5 Volume III: Administrative and Cost Volume, Other Administrative Requirements). 2. Amend the RPP, Attachment A – Statement of Objectives (SOO) as follows: - Update the Revised Date (page 1). - Update language throughout to clarify the Government’s intent regarding drug versus product. - page 1, section 1. Purpose/Objective, second and third paragraphs - page 2, section 4 Objectives, second, third and fifth paragraphs - page 3, section 4 Objectives, first paragraph - page 5, Desirable prototype characteristics and performance, first paragraph - Revise the following Desirable prototype characteristics and performance: (2), (6), (9), and (13) (page 5 and page 6). - Revise the following Deliverables: Deliverable 3 and Deliverable 12 (page 7 and page 9, respectively). 3. Answer questions received from potential performers (see RPP Amendment 0001, Attachment 1). There are no other changes. | 65% | Solicitation | 08/14/2026 |
62% | Special Notice | 11/02/2026 |
Additional Details
Solicitation Number
HT9427RFI2027AZRP
Archive Date
Dec 19, 2026
Office Address
FORT DETRICK, MD, 21702